JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
December 2026
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT04644770A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07223125A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsJanssen Research & Development, LLC · Advanced-stage Solid TumorsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT02609776Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerJanssen Research & Development, LLC · Non-Small-Cell Lung CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04662580ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerJanssen Research & Development, LLC · Metastatic Prostate CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 6, 2027Sponsor estimate | NCT05784441A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Janssen Research & Development, LLC · Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | JNJLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Jan 7, 2027Sponsor estimate | NCT07319871A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerJanssen Research & Development, LLC · Prostatic Neoplasms | JNJLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2027Sponsor estimate | NCT05908734A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell Lung | JNJLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 6, 2027Sponsor estimatePhase 1NCT05784441A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Janssen Research & Development, LLC · Relapsed or Refractory B Cell Non-Hodgkin LymphomaActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT07319871A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1/Phase 2NCT05908734A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 12, 2027Sponsor estimate | NCT04077463A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell Lung | JNJLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Feb 16, 2027Sponsor estimate | NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · Healthy | JNJLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Feb 12, 2027Sponsor estimatePhase 1NCT04077463A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2027Sponsor estimatePhase 1NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · HealthyRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.